Yahoo Web Search

Search results

1. • 

     BioMarin drops drug programs in pipeline cull

     BioPharma Dive via Yahoo Finance· 17 hours ago

     Dive Insight: BioMarin is revamping its research and development priorities as it struggles to win reimbursement for Roctavian, the first marketed gene ...

2. • 

     SK pharmteco to manufacture Ferring Pharmaceuticals’ gene therapy for bladder cancer

     BioPharma-Reporter· 4 days ago

     According to both companies, this scale up secures future long-term supply of Adstiladrin to meet...

3. • 

     MeiraGTx Holdings plc (NASDAQ:MGTX): Is Breakeven Near?

     Simply Wall St. via Yahoo Finance· 17 hours ago

     MeiraGTx Holdings plc (NASDAQ:MGTX) is possibly approaching a major achievement in its business, so...

4. • Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell...

     Morningstar· 3 days ago

     Oral presentations include updated results from clinical study of otoferlin gene therapy DB-OTO demonstrating restoration in children with profound genetic ...

5. • Affinia Therapeutics to Present Data on Novel Cardiotropic and BBB-Penetrant AAV Capsids and...

     WTNH-TV New Haven· 3 days ago

     Affinia Therapeutics ("Affinia"), an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors ...

6. • Under new leadership, BioMarin axes 4 candidates and centers on 3 assets

     FierceBiotech· 15 hours ago

     After BioMarin’s new leadership conducted a “strategic R&D asset review,” three of its “most productive” assets are being prioritized, leaving four candidates on the wayside. First up on the ...

7. • Investing in Taysha Gene Therapies Inc

     Knox Daily· 4 days ago

     Taysha Gene Therapies Inc’s filing revealed that its 10% Owner Manning Paul B acquired Company’s shares for reported $0.16 million on Nov 17 ’23. In the deal valued at $1.63 per share,100,000 ...

8. • ...Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of...

     Morningstar· 7 days ago

     GA affects approximately 1 million people in the United States alone.

9. • Ascend Hires Scott Law as COO and Continues Strengthening Foundation

     WPRI Providence· 2 days ago

     Ascend Advanced Therapies (Ascend), an end-to-end gene therapy development partner, has announced the addition of industry veteran Scott Law as Chief Operations ...

10. • ... to Present New Data on its Wholly Owned Gene Therapy Programs in Genetic Epilepsy and...

      The Record Gazette· 3 days ago

      Capsida Biotherapeutics (PRNewsfoto/Capsida Biotherapeutics)